Edition:
United Kingdom

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

0.63USD
17 May 2019
Change (% chg)

-- (--)
Prev Close
$0.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
54,248
52-wk High
$7.80
52-wk Low
$0.62

Latest Key Developments (Source: Significant Developments)

Cellect Biotechnology Ltd QTRLY Total Comprehensive Loss Per Share $0.008
Monday, 18 Mar 2019 

Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS AND RECENT CORPORATE PROGRESS.CELLECT BIOTECHNOLOGY LTD QTRLY TOTAL COMPREHENSIVE LOSS PER SHARE $0.008.  Full Article

Cellect Biotechnology Determined To Withdraw Sole Proposal To Elect External Director At Co's Extraordinary Meeting Of Shareholders
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY - DETERMINED TO WITHDRAW SOLE PROPOSAL TO ELECT EXTERNAL DIRECTOR AT CO'S EXTRAORDINARY MEETING OF SHAREHOLDERS.CELLECT BIOTECHNOLOGY - DETERMINED TO WITHDRAW PROPOSAL DUE TO CONFLICT OF INTEREST DISQUALIFIED CANDIDATE FROM SERVING AS EXTERNAL DIRECTOR.CELLECT BIOTECHNOLOGY - INTENDS TO PROPOSE NEW CANDIDATE FOR ELECTION AS AN EXTERNAL DIRECTOR, TO CONVENE A SHAREHOLDERS’ MEETING.  Full Article

Cellect Biotechnology Net Loss For Q2 $0.013 Per Share
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD - NET LOSS FOR Q2 WAS $0.013 PER SHARE & $0.25 PER ADS.  Full Article

Cellect Biotechnology Granted Key European Patent For Its Stem Cell Selection Technology
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY GRANTED KEY EUROPEAN PATENT FOR ITS STEM CELL SELECTION TECHNOLOGY.  Full Article

Cellect Biotechnology Q4 Loss Per Share ‍$0.008​
Monday, 19 Mar 2018 

March 19 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD - QTRLY LOSS PER SHARE ‍$0.008​.CELLECT BIOTECHNOLOGY - ‍CASH AND CASH EQUIVALENTS TOTALED $8.0 MILLION AS OF DEC 31, 2017, COMPARED TO $9.4 MILLION ON SEPT 30, 2017​.  Full Article

Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION.CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY​.CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​.  Full Article

Cellect Biotechnology reports Q3 ‍loss $0.02/shr​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology Ltd provides corporate update and reports third quarter 2017 financial results.Cellect Biotechnology Ltd - qtrly ‍loss per share $0.02​.  Full Article

Cellect Biotechnology announces $4.3 million raise in a registered direct offering
Thursday, 7 Sep 2017 

Sept 7 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology announces $4.3 million raise in a registered direct offering.Cellect Biotechnology Ltd - ‍entered into securities purchase agreements with certain accredited investors to receive gross proceeds of $4.3 million​.Cellect Biotechnology Ltd -in connection with offering, co will issue 531,136 adss at a purchase price of $8.10 per ads.  Full Article

FDA grants orphan drug status to Cellect's Apograft for acute GVHD and chronic GVHD
Tuesday, 5 Sep 2017 

Sept 5 (Reuters) - Cellect Biotechnology Ltd :FDA grants orphan drug status to Cellect's Apograft for acute GVHD and chronic GVHD.‍FDA granted orphan drug designation for Apograft for prevention of acute and chronic GVHD in transplant patients​.  Full Article

Cellect Biotechnology - Locust Walk engaged to seek strategic licensing deals and global pharma partnerships for commercialization of Cellect's Apograft
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology - Locust Walk engaged to seek strategic licensing deals and global pharma partnerships for commercialization of Cellect's Apograft.  Full Article

No consensus analysis data available.